H-Cyte Inc (OTCMKTS:HCYT) was one of the biggest losers in Tuesday’s trading session after the company released news.
Market Action
On Tuesday, HCYT stock soared 131% to $0.0720 with more than 18.33 million shares, compared to its average volume of 65k shares. The stock has moved within a range of $0.0370 – 0.2890 after opening the trade at $0.379.
Major Trigger:
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health
Key Highlights:
- H-Cyte announced the publication of its clinical observational study titled, “Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.”
- The study, published in the peer-reviewed Journal of Regenerative Medicine & Biology Research, relates to the Company’s innovative autologous treatment, and concludes that patients experienced a statistically significant improvement in pulmonary function at both 3 months and 12 months (FEV1 % predicted) and quality of life (CCQ score) post treatment. The study may be accessed at https://athenaeumpub.com/longitudinal-assessment-of-fev1-change-following-autologous-cellular-therapy/.
- The study, which involved 281 participants with COPD (chronic obstructive pulmonary disease). demonstrated that 23% of patients saw an improvement in their lung function by at least 15% from baseline at 3 months post-treatment (FEV1 measures), and 29% of patients saw the same improvement at 12 months post-treatment. At 3 months and 12 months post-treatment, 64% and 67% of participants respectively, experienced a significant quality of life improvement.
- All participants tolerated the procedure well, and there were no reportable adverse or unexpected events. All participants were able to stay on their physician prescribed medications to manage their COPD. The efficacy, quality of life and safety shown in this study were above and beyond that achieved with their maintenance therapy.
 Stock Get Special Attention: What’s The Buzz?){kind=link}